Trial Profile
An Open-label Study of Xeloda Plus Avastin at Time of Disease Progression in Treatment-naive Women With HER2-negative Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 21 Jul 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Actual number of patients (108) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.